NCT03600883 2026-03-16A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)AmgenPhase 1/2 Active not recruiting713 enrolled 1 FDA